Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AtaiBeckley Inc. | COMP360 - (COMPASS) | Treatment Resistant Depression (TRD) | Phase 2b | Data Released | Oral | Psychiatric |
| Atara Biotherapeutics Inc. | ATA188 - (EMBOLD) | Multiple sclerosis | Phase 2 | Ongoing | Intravenous | Neurology |
| Atea Pharmaceuticals Inc. | AT-752 - (DEFEND-2) | Dengue | Phase 2 | Data Released | Oral | N/A |
| Atea Pharmaceuticals Inc. | AT-527 - (MORNINGSKY) | COVID-19 | Phase 3 | Trial Discontinued | oral | COVID-19 |
| Atea Pharmaceuticals Inc. | Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD) | Hepatitis C Virus (HCV) | Phase 3 | Enrollment Initiation | Oral | Antiviral |
| Atea Pharmaceuticals Inc. | Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD) | Hepatitis C Virus (HCV) | Phase 3 | Enrollment Initiation | Oral | Antiviral |
| Atea Pharmaceuticals Inc. | SVR12 in combination of bemnifosbuvir and ruzasvir - (C-BEYOND) | Hepatitis C virus (HCV) | Phase 3 | Enrollment Conclusion | Oral | Antiviral |
| Atea Pharmaceuticals Inc. | AT-527 (Outpatient Setting) - (MOONSONG) | COVID-19 | Phase 2 | Trial Discontinued | oral | COVID-19 |
